Novavax (NVAX) Total Non-Current Liabilities (2010 - 2026)
Novavax (NVAX) posted quarterly Total Non-Current Liabilities of $994.7 million for Q1 2026, down 5.71% year-over-year from $1.1 billion in Q1 2025, and down 6.62% quarter-over-quarter from $1.1 billion in Q4 2025.
Novavax (NVAX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Novavax's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $994.7 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 5.71% year-over-year to $994.7 million; the TTM figure through Mar 2026 stood at $994.7 million (down 5.71% YoY), while the FY2025 annual figure was $1.1 billion, down 41.62% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $994.7 million, down from $1.1 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $3.0 billion in Q2 2022, with the low at $994.7 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $1.9 billion (2024), against an average of $2.0 billion.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 74.64% in 2022, then slumped 47.19% in 2025.
- Novavax's Total Non-Current Liabilities stood at $2.8 billion in 2022, then slipped by 12.54% to $2.5 billion in 2023, then dropped by 26.46% to $1.8 billion in 2024, then plunged by 41.62% to $1.1 billion in 2025, then slipped by 6.62% to $994.7 million in 2026.
- Business Quant data shows NVAX's Total Non-Current Liabilities at $994.7 million in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 980.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 980.54 Mn |
| Mar 31, 2026 | 994.68 Mn |
| Dec 31, 2025 | 1.07 Bn |
| Sep 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 1.01 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.82 Bn |
| Sep 30, 2024 | 1.92 Bn |
| Jun 30, 2024 | 1.92 Bn |
| Mar 31, 2024 | 1.87 Bn |
| Dec 31, 2023 | 2.48 Bn |
| Sep 30, 2023 | 2.30 Bn |
| Jun 30, 2023 | 2.40 Bn |
| Mar 31, 2023 | 2.39 Bn |
| Dec 31, 2022 | 2.84 Bn |
| Sep 30, 2022 | 2.73 Bn |
| Jun 30, 2022 | 2.97 Bn |
| Mar 31, 2022 | 2.70 Bn |
| Dec 31, 2021 | 2.89 Bn |
| Sep 30, 2021 | 2.08 Bn |